Welcome to World Class Retina Care

Our practice was established in 1980 in central Phoenix. Since then, we have grown to include more than 35 locations throughout Arizona, providing improved access to the highest quality medical care. We are proud to have become Arizona’s largest and most experienced ophthalmology practice focused specifically on the diagnosis and management of the retina and vitreous.

At RCA, we believe in providing you with professional, attentive, and personal care while utilizing the latest technology and treatments. We accept new patients every day, and urgent or emergency referrals are seen the same day.

Find Your Location Today

Take charge of your eye health!

Making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. we encourage everyone to take charge of their eye health and preserve their sight by following some simple tips.

Click here for more!

Latest News From RCA

Pravin U. Dugel, MD: Clinical Effectiveness of Switching Between Ranibizumab and Aflibercept in Treatment of Neovascular AMD: US Real-World Outcomes

Purpose: The purpose of this article is to examine visual acuity (VA) outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes switching between ranibizumab and aflibercept in routine clinical practice. Methods: Electronic medical records were used to identify nAMD eyes receiving ranibizumab or aflibercept with 12 months’ follow-up since switching antivascular endothelial growth… Read More »

Dr. Pravin U. Dugel – HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration

Pravin U. Dugel, Adrian Koh, Yuichiro Ogura, Glenn Jaffe, Ursula Schmidt-Erfurth, David Brown, Andre V. Gomes, James Warburton, Andreas Weichselberger, Frank G. Holz Abstract ObjectiveTwo similarly designed, phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (AMD). DesignDouble-masked, multicenter, active-controlled, randomized trials. Patients(N = 1817) with untreated,… Read More »

Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. VBS 2019

Pravin Dugel, MD, R. Ross Lakhanpal, MD   Channels: Retina | Posted 4/5/2019 Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. In Dr. Dugel’s view, the informatics platforms used in other fields could translate to retina and, when they arrive, will change the preparation and… Read More »